Patients had received three or fewer lines of cytotoxic chemotherapy for advanced breast cancer.
Previous platinum therapy in the setting of early breast cancer was permitted if it was completed at least 6 months before progressive disease or if there was no objective progression while on platinum therapy in the advanced-disease setting.
Hormone receptor–positive and hormone receptor–negative patients were enrolled.Median PFS was significantly longer in the talazoparib group than in the standard therapy group (8.6 months vs.
5.6 months; HRdisease progression or death, 0.54; 95% CI, 0.41–0.71;P< .001).Benefits were observed in all subgroups, although CIs were wide in the subgroup of patients who had received previous platinum therapy.Median OS did not differ between the two groups (22.3 months vs.